BioCentury | Nov 13, 2019
Finance

Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

...Corp. holds an exclusive, worldwide license from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to tralesinidase alfa (formerly BMN 250...
...near term. Targets IGF-2 - Insulin-like growth factor 2 NAGLU - N-acetylglucosaminidase α Paul Bonanos, Associate Editor BMN 250 BioMarin...
BioCentury | Oct 24, 2019
Finance

Allievex, backed by Pappas and Novo, scoops up BioMarin ultra-rare disease assets

...Corp. holds an exclusive, worldwide license from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to tralesinidase alfa (formerly BMN 250...
...near term. Targets IGF-2 - Insulin-like growth factor 2 NAGLU - N-acetylglucosaminidase α Paul Bonanos, Associate Editor BMN 250 BioMarin...
BioCentury | Nov 10, 2017
Clinical News

BioMarin reports Phase I/II data for BMN 250 in mucopolysaccharidosis IIIB

...syndrome) in the dose-escalation portion of the Phase I/II BMN 250-201 trial showing that intracerebroventricular (ICV) BMN 250...
...all 3 patients, BMN 250 decreased liver size and reduced cerebrospinal fluid (CSF) heparan sulfate levels. BMN 250...
...as well as patients from the dose-escalation portion of BMN 250-201 to receive once-weekly 300 mg BMN 250...
BioCentury | May 2, 2016
Clinical News

BMN 250: Phase I/II started

...to evaluate BMN 250 given via intracerebroventricular infusion. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Product: BMN 250...
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...response to the fusion protein. BioMarin has the NAGLU-IGF-2 fusion protein used in the study (BMN 250...
BioCentury | Jun 16, 2014
Regulation

Signal crossing

FDA 's workshop on neurological symptoms in inborn errors of metabolism revealed conflicts between how caregivers would like symptoms assessed and what drug companies need to test to get therapies approved. The June 10 workshop...
Items per page:
1 - 6 of 6